$65.77 today and gaining We are on a roll !
Interview With Rick G. CEO Abbvie Inc.
- Thread starter anonymous
- Start date
-
- Tags
- None
$65.77 today and gaining We are on a roll !
We have an old friend of big Pharma in new FDA commissioner Scott Gottlieb He is an advocate of faster, flexible approval of drugs especially where it comes to diseases of material unmet need. Looks like we got a inside player good ol boy to help us BIG LEAGUE in ONC and other areas. Device company's will get slammed but NOT Pharma.
I think you are a little too optimistic here. Historically didn't we push thru the approvals by donations to the key politicians etc?. Can't do that now with this guy.
We wont have to lobby or donate on the scale we did under Obamas FDA. The FDA swamp is being drained as we speak.
$66 and Climbing
AbbVie Common Stock
NYSE: ABBV - Mar 24, 11:38 AM EDT
$66.00 USD +0.35 (0.53%)
AbbVie Common Stock
NYSE: ABBV - Mar 24, 11:38 AM EDT
$66.00 USD +0.35 (0.53%)
If that's really true then we may be in trouble, the donations paved the way..
3 Things You Probably Didn't Know About AbbVie Inc.
Among all drug stocks, AbbVie stands near the top in several categories.
Keith Speights
(TMFFishBiz)
Mar 28, 2017 at 7:03AM
Since its spinoff from Abbott Laboratories (NYSE:ABT) in 2013, AbbVie (NYSE:ABBV) has become one of the hottest big biotech stocks on the market. When AbbVie was formed, its market cap was close to Abbott's. Now, however, the biotech's market cap is nearly 35% higher than that of its parent company.
There's much for investors to like about AbbVie now -- but there are also some reasons for concern. Here are three things you might not know about this successful biotech.
IMAGE SOURCE: GETTY IMAGES.
1. One of the fastest-growing dividends
You probably already know that AbbVie currently boasts the highest dividend yield of any biotech stock. The company's yield of 3.9% easily tops the next-best contenders, Gilead Sciences and Amgen.
But did you know that AbbVie's dividend growth is among the highest of any stock on the market, regardless of industry? Over the last three years, AbbVie's dividend increased by an average annual rate of more than 17%. If we include Abbott's dividend track record, AbbVie has increased its dividend for 45 years in a row.
Even better, AbbVie appears to be poised to keep the dividend hikes coming. The company currently uses less than 63% of its earnings to fund the dividend program. That leaves plenty of room for more increases, especially considering that AbbVie's earnings are expected to grow significantly in the coming years.
2. One of the strongest product portfolios
Since Abbott spun it off, AbbVie has primarily been known for its huge blockbuster autoimmune disease drug, Humira. Sales for the company's other products were so much smaller in comparison that I nicknamed AbbVie's lineup "Humira and the seven dwarfs." That moniker isn't applicable today.
The 2015 acquisition of Pharmacyclics allowed AbbVie to pick up Imbruvica. The cancer drug could generate annual revenue of $5 billion by 2020 with approval of additional indications. AbbVie's buyout last year of Stemcentrx brought another cancer drug, Rova-T, into its pipeline. Rova-T is expected to launch next year and could reach peak annual sales of up to $5 billion. AbbVie partnered with Roche to develop yet another cancer drug, Venclexta, which could hit annual sales of up to $2 billion by 2020.
Humira could be joined in the next couple of years by two experimental autoimmune-disease candidates in AbbVie's pipeline. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. Additional indications could also follow for both drugs.
3. One of the biggest debt loads
The acquisitions of Pharmacyclics and Stemcentrx came at a cost. AbbVie now has a total debt of nearly $37 billion. The only drugmaker with a higher level of debt is Pfizer. However, if you counted only long-term debt, AbbVie would rank at the top among all biopharmaceutical companies.
The buyout of Stemcentrx last year caused Moody's Investor Service to downgrade AbbVie's senior unsecured long-term rating to Baa2 from Baa1, which reflects a moderate credit risk. AbbVie's shareholders probably don't want the company to take on much more debt.
However, AbbVie's strong earnings and cash flow should allow the biotech to easily service its current debt. Earnings growth could also enable AbbVie to retire some of the debt more quickly, if it chose to do so.
One thing no one knows
There's at least one thing that no one knows about AbbVie: When will Humira's sales begin to fall? That uncertainty could make some investors wary of buying the stock.
I think, though, with its strong dividend and portfolio full of potential winners, AbbVie remains a smart pick. Abbott's spinoff has paid off nicely so far. My take is that it will continue to pay off for at least a few years to come.
Forget AbbVie: "Total conviction" buy signal issued
The Motley Fool's co-founders, David and Tom Gardner, rarely agree on a stock. But when they do, their picks have beaten the market by 6X on average.*
That's why many investors consider their joint stamp of approval to be a "total conviction" signal to buy. The Motley Fool recently announced a new "total conviction" stock…and it wasn't AbbVie!
Among all drug stocks, AbbVie stands near the top in several categories.
Keith Speights
(TMFFishBiz)
Mar 28, 2017 at 7:03AM
Since its spinoff from Abbott Laboratories (NYSE:ABT) in 2013, AbbVie (NYSE:ABBV) has become one of the hottest big biotech stocks on the market. When AbbVie was formed, its market cap was close to Abbott's. Now, however, the biotech's market cap is nearly 35% higher than that of its parent company.
There's much for investors to like about AbbVie now -- but there are also some reasons for concern. Here are three things you might not know about this successful biotech.
IMAGE SOURCE: GETTY IMAGES.
1. One of the fastest-growing dividends
You probably already know that AbbVie currently boasts the highest dividend yield of any biotech stock. The company's yield of 3.9% easily tops the next-best contenders, Gilead Sciences and Amgen.
But did you know that AbbVie's dividend growth is among the highest of any stock on the market, regardless of industry? Over the last three years, AbbVie's dividend increased by an average annual rate of more than 17%. If we include Abbott's dividend track record, AbbVie has increased its dividend for 45 years in a row.
Even better, AbbVie appears to be poised to keep the dividend hikes coming. The company currently uses less than 63% of its earnings to fund the dividend program. That leaves plenty of room for more increases, especially considering that AbbVie's earnings are expected to grow significantly in the coming years.
2. One of the strongest product portfolios
Since Abbott spun it off, AbbVie has primarily been known for its huge blockbuster autoimmune disease drug, Humira. Sales for the company's other products were so much smaller in comparison that I nicknamed AbbVie's lineup "Humira and the seven dwarfs." That moniker isn't applicable today.
The 2015 acquisition of Pharmacyclics allowed AbbVie to pick up Imbruvica. The cancer drug could generate annual revenue of $5 billion by 2020 with approval of additional indications. AbbVie's buyout last year of Stemcentrx brought another cancer drug, Rova-T, into its pipeline. Rova-T is expected to launch next year and could reach peak annual sales of up to $5 billion. AbbVie partnered with Roche to develop yet another cancer drug, Venclexta, which could hit annual sales of up to $2 billion by 2020.
Humira could be joined in the next couple of years by two experimental autoimmune-disease candidates in AbbVie's pipeline. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. Additional indications could also follow for both drugs.
3. One of the biggest debt loads
The acquisitions of Pharmacyclics and Stemcentrx came at a cost. AbbVie now has a total debt of nearly $37 billion. The only drugmaker with a higher level of debt is Pfizer. However, if you counted only long-term debt, AbbVie would rank at the top among all biopharmaceutical companies.
The buyout of Stemcentrx last year caused Moody's Investor Service to downgrade AbbVie's senior unsecured long-term rating to Baa2 from Baa1, which reflects a moderate credit risk. AbbVie's shareholders probably don't want the company to take on much more debt.
However, AbbVie's strong earnings and cash flow should allow the biotech to easily service its current debt. Earnings growth could also enable AbbVie to retire some of the debt more quickly, if it chose to do so.
One thing no one knows
There's at least one thing that no one knows about AbbVie: When will Humira's sales begin to fall? That uncertainty could make some investors wary of buying the stock.
I think, though, with its strong dividend and portfolio full of potential winners, AbbVie remains a smart pick. Abbott's spinoff has paid off nicely so far. My take is that it will continue to pay off for at least a few years to come.
Forget AbbVie: "Total conviction" buy signal issued
The Motley Fool's co-founders, David and Tom Gardner, rarely agree on a stock. But when they do, their picks have beaten the market by 6X on average.*
That's why many investors consider their joint stamp of approval to be a "total conviction" signal to buy. The Motley Fool recently announced a new "total conviction" stock…and it wasn't AbbVie!
3 Things You Probably Didn't Know About AbbVie Inc.
Among all drug stocks, AbbVie stands near the top in several categories.
Keith Speights
(TMFFishBiz)
Mar 28, 2017 at 7:03AM
Since its spinoff from Abbott Laboratories (NYSE:ABT) in 2013, AbbVie (NYSE:ABBV) has become one of the hottest big biotech stocks on the market. When AbbVie was formed, its market cap was close to Abbott's. Now, however, the biotech's market cap is nearly 35% higher than that of its parent company.
There's much for investors to like about AbbVie now -- but there are also some reasons for concern. Here are three things you might not know about this successful biotech.
IMAGE SOURCE: GETTY IMAGES.
1. One of the fastest-growing dividends
You probably already know that AbbVie currently boasts the highest dividend yield of any biotech stock. The company's yield of 3.9% easily tops the next-best contenders, Gilead Sciences and Amgen.
But did you know that AbbVie's dividend growth is among the highest of any stock on the market, regardless of industry? Over the last three years, AbbVie's dividend increased by an average annual rate of more than 17%. If we include Abbott's dividend track record, AbbVie has increased its dividend for 45 years in a row.
Even better, AbbVie appears to be poised to keep the dividend hikes coming. The company currently uses less than 63% of its earnings to fund the dividend program. That leaves plenty of room for more increases, especially considering that AbbVie's earnings are expected to grow significantly in the coming years.
2. One of the strongest product portfolios
Since Abbott spun it off, AbbVie has primarily been known for its huge blockbuster autoimmune disease drug, Humira. Sales for the company's other products were so much smaller in comparison that I nicknamed AbbVie's lineup "Humira and the seven dwarfs." That moniker isn't applicable today.
The 2015 acquisition of Pharmacyclics allowed AbbVie to pick up Imbruvica. The cancer drug could generate annual revenue of $5 billion by 2020 with approval of additional indications. AbbVie's buyout last year of Stemcentrx brought another cancer drug, Rova-T, into its pipeline. Rova-T is expected to launch next year and could reach peak annual sales of up to $5 billion. AbbVie partnered with Roche to develop yet another cancer drug, Venclexta, which could hit annual sales of up to $2 billion by 2020.
Humira could be joined in the next couple of years by two experimental autoimmune-disease candidates in AbbVie's pipeline. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. Additional indications could also follow for both drugs.
3. One of the biggest debt loads
The acquisitions of Pharmacyclics and Stemcentrx came at a cost. AbbVie now has a total debt of nearly $37 billion. The only drugmaker with a higher level of debt is Pfizer. However, if you counted only long-term debt, AbbVie would rank at the top among all biopharmaceutical companies.
The buyout of Stemcentrx last year caused Moody's Investor Service to downgrade AbbVie's senior unsecured long-term rating to Baa2 from Baa1, which reflects a moderate credit risk. AbbVie's shareholders probably don't want the company to take on much more debt.
However, AbbVie's strong earnings and cash flow should allow the biotech to easily service its current debt. Earnings growth could also enable AbbVie to retire some of the debt more quickly, if it chose to do so.
One thing no one knows
There's at least one thing that no one knows about AbbVie: When will Humira's sales begin to fall? That uncertainty could make some investors wary of buying the stock.
I think, though, with its strong dividend and portfolio full of potential winners, AbbVie remains a smart pick. Abbott's spinoff has paid off nicely so far. My take is that it will continue to pay off for at least a few years to come.
Forget AbbVie: "Total conviction" buy signal issued
The Motley Fool's co-founders, David and Tom Gardner, rarely agree on a stock. But when they do, their picks have beaten the market by 6X on average.*
That's why many investors consider their joint stamp of approval to be a "total conviction" signal to buy. The Motley Fool recently announced a new "total conviction" stock…and it wasn't AbbVie!
whoever posted this better realize it has a lot of misstatements. Idiot..
The only idiot is you parrot. Now get back to the lonely cellar and talk to yourself there !
Article is accurate and it bugs you. Ha Ha too bad
Article is accurate and it bugs you. Ha Ha too bad
The acquisitions of Pharmacyclics and Stemcentrx came at a cost. AbbVie now has a total debt of nearly $37 billion. The only drugmaker with a higher level of debt is Pfizer. However, if you counted only long-term debt, AbbVie would rank at the top among all biopharmaceutical companies.
Abbvie is still # 1 in my book though. Let's go Rick, keep that stock pumped up.
UPDATE: TG Therapeutics stock rises 4% on positive late-stage cancer trial results
TG Therapeutics Inc. TGTX, shares rose 3.7% in morning trade Monday after the company said a late-stage clinical trial for its TG-1101 with AbbVie ABBV, +0.39%and Johnson & Johnson's JNJ, +0.22% Imbruvica had positive results. The drug combination was tested in patients with previously-treated high risk Chronic Lymphocytic Leukemia, with 126 patients enrolled in the phase 3 trial. The combination showed a statistically significant improvement in overall response rate, the trial's primary endpoint, the company said. TG Therapeutics said it intends to pursue accelerated approval when it shares the results with the Food and Drug Administration later this year. TG Therapeutics shares have risen 168.2% over the last three months to $14.37, compared with a 2.2% rise in the S&P 500 SPX, -0.12%
In April 2012 TGTX stock was .12¢ YUGE 61 month return. Heard Rick got in BIG on this back then and is sitting on mega gains.
Selective inhibition of the JAK1 is driving stock to near all time highs. Phase 3 program will drive it to $73 if successful. Ricky has a gold mine and shareholders are ecstatic.
Rickys salary in 2015 was a YUGE $20.81 million. In 2016 it was higher coming in at a staggering $20.97 million Rickys perks also shot up, to $859,216 from $791,063 Personal air travel was UPPED. Rick got around on LAND TOO netting $19,362 in corporate care benefits for limos/drivers compared with last year’s $17,303.
How is this man so smart and cunning ? He wasn't brainwashed by College professors. Ricks a "Mans Man"
How is this man so smart and cunning ? He wasn't brainwashed by College professors. Ricks a "Mans Man"
Yeah BABY only .95 cents away from all time high of $70.40 !!!!!!!!!!!!!!!
AbbVie Common Stock
NYSE: ABBV - Jun 9
$69.45 USD UP 0.59 (0.86%)
AbbVie Common Stock
NYSE: ABBV - Jun 9
$69.45 USD UP 0.59 (0.86%)
I'm too busy thinkin' about my baby
Oh I ain't got time for nothin' else
Too busy thinkin' about my baby
Ain't got time for nothing else
'Cause I'm just a fellow with a one track mind
And when it comes to thinkin about
Anything but my baby
I just DONT HAVE THE TIME
Oh I ain't got time for nothin' else
Too busy thinkin' about my baby
Ain't got time for nothing else
'Cause I'm just a fellow with a one track mind
And when it comes to thinkin about
Anything but my baby
I just DONT HAVE THE TIME
(Chorus)
He's too busy thinking .......about his baby...and he ain't got time for nuttin else
YUGE stock gains that month $74 and climbing
$$$$ Ca Ching $$$$
He's too busy thinking .......about his baby...and he ain't got time for nuttin else
YUGE stock gains that month $74 and climbing
$$$$ Ca Ching $$$$
Thanks to all employees who participated in AbbVie’s Week of Possibilities, It was a YUGE success !
Richard Gonzalez CEO
Richard Gonzalez CEO
Rick didn't listen and then he had to open his big Fkn mouth all scared of Trump on earning call saying no price increase in Humira which btw is already negotiated into 2018 thus causing stock to drop and stay down. I got in at $58 in fall and just bailed at $71.40 DUMP IT OR SHORT IT. Must be the HPD mentality coming out in him.